BDX Gains 0.48% With $510M Volume Ranking 205th as Insiders Sell Shares and Pension Fund Boosts Stake 7.6%

Generated by AI AgentAinvest Market Brief
Friday, Aug 15, 2025 7:58 pm ET1min read
BDX--
Aime RobotAime Summary

- BDX shares rose 0.48% with $510M volume on August 15, 2025, as insiders sold shares and a pension fund increased its stake by 7.6%.

- Q3 earnings exceeded estimates by $0.28, revenue grew 10.4% to $5.51B, and analysts adjusted outlooks amid strategic investments.

- The company announced a $1.04/share dividend and $35M in Nebraska facility expansion, securing FDA approval for a rapid COVID-19 test.

- A backtest of a volume-based trading strategy showed 0.98% average daily returns over 365 days, highlighting short-term momentum capture.

On August 15, 2025, BectonBDX--, Dickinson and Company (BDX) rose 0.48% with a trading volume of $510 million, ranking 205th in daily activity. Recent insider activity revealed Director Claire Fraser and Executive Vice President Michael David Garrison reduced holdings by 3.59% and 19.52%, respectively, through stock sales totaling $579,206 in the last three months. Meanwhile, National Pension Service increased its stake by 7.6% in the first quarter, holding 0.25% of the company’s shares valued at $162.15 million.

The company reported Q3 earnings of $3.68 per share, surpassing estimates by $0.28, with revenue rising 10.4% year-over-year to $5.51 billion. Institutional ownership remains strong, with 86.97% held by hedge funds and pension funds. Analysts have adjusted their outlook, with some lowering ratings to “Market Perform” or “Hold” while others raised price targets, reflecting cautious optimism amid the company’s strategic investments in manufacturing expansion and diagnostic innovations.

Becton, Dickinson announced a quarterly dividend of $1.04 per share, set to be paid on September 30, yielding 2.1%. The firm also plans to invest $35 million in a Nebraska facility to boost prefilled syringe production and recently secured FDA clearance for a rapid point-of-care COVID-19 test. These moves underscore efforts to strengthen market position and capitalize on healthcare demand.

A backtest of a strategy buying the top 500 stocks by volume and holding for one day from 2022 to 2025 showed a 0.98% average daily return, with a total return of 31.52% over 365 days. This highlights the strategy’s capture of short-term momentum, though volatility and timing risks remain evident.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet